Infiltrating mast cells promote renal cell carcinoma angiogenesis by modulating PI3K → AKT → GSK3β → AM signaling

Oncogene

Volumn 36, Issue 20, 2017, Pages 2879-2888

  Chen, Y ^a   Li, C ^b,c   Xie, H ^a   Fan, Y ^a   Yang, Z ^a   Ma, J ^a   He, D ^a   Li, L ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c Beijing Jianlan Institute of Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN MODULATING PROTEIN; BEVACIZUMAB; CROMOGLYCATE DISODIUM; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; ADRENOMEDULLIN; BIOLOGICAL MARKER;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; ENDOTHELIUM CELL; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KIDNEY TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NEUTROPHIL CHEMOTAXIS; PATHOLOGY; RENAL CELL CARCINOMA; TUMOR CELL LINE; XENOGRAFT;

ADRENOMEDULLIN; ANIMALS; BIOMARKERS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CHEMOTAXIS, LEUKOCYTE; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GLYCOGEN SYNTHASE KINASE 3 BETA; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MAST CELLS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 85010869414     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.442     Document Type: Article

References (43)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Cairns P. Renal cell carcinoma. Cancer Biomark 2010; 9: 461-473.
3. Kornakiewicz A, Solarek W, Bielecka ZF, Lian F, Szczylik C, Czarnecka AM. Mammalian target of rapamycin inhibitors resistance mechanisms in clear cell renal cell carcinoma. Curr Signal Transduct Ther 2014; 8: 210-218.
4. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, et al. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res 2015; 3: 1017-1029.
5. Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, et al. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One 2011; 6: E19144.
6. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006; 94: 614-619.
7. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373: 1119-1132.
8. Shen C, Kaelin WG Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 2013; 23: 18-25.
9. Tuna B, Yorukoglu K, Unlu M, Mungan MU, Kirkali Z. Association of mast cells with microvessel density in renal cell carcinomas. Eur Urol 2006; 50: 530-534.
10. Toge H, Inagaki T, Kojimoto Y, Shinka T, Hara I. Angiogenesis in renal cell carcinoma: The role of tumor-associated macrophages. Int J Urol 2009; 16: 801-807.
11. Ning H, Shao QQ, Ding KJ, Gao DX, Lu QL, Cao QW, et al. Tumor-infiltrating regulatory T cells are positively correlated with angiogenic status in renal cell carcinoma. Chin Med J (Engl) 2012; 125: 2120-2125.
12. Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: Angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 2009; 1796: 19-26.
13. Crivellato E, Nico B, Ribatti D. Mast cells and tumour angiogenesis: New insight from experimental carcinogenesis. Cancer Lett 2008; 269: 1-6.
14. Dang Q, Li L, Xie H, He D, Chen J, Song W, et al. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells-4 androgen receptor (AR)-4 miRNA32 signals. Mol oncol 2015; 9: 1241-1251.
15. Li L, Dang Q, Xie H, Yang Z, He D, Liang L, et al. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population. Oncotarget 2015; 6: 14179-14190.
16. Shi GP, Lindholt JS. Mast cells in abdominal aortic aneurysms. Curr Vasc Pharmacol 2013; 11: 314-326.
17. Safdari Y, Khalili M, Ebrahimzadeh MA, Yazdani Y, Farajnia S. Natural inhibitors of PI3K/AKT signaling in breast cancer: Emphasis on newly-discovered molecular mechanisms of action. Pharmacol res 2015; 93: 1-10.
18. Wickenden JA, Watson CJ. Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: A play in 3 Akts. Breast Cancer Res 2010; 12: 202.
19. Galinsky DS, Nechushtan H. Mast cells and cancer-no longer just basic science. Crit Rev Oncol Hematol 2008; 68: 115-130.
20. Siebenhaar F, Metz M, Maurer M. Mast cells protect from skin tumor development and limit tumor growth during cutaneous de novo carcinogenesis in a Kit-dependent mouse model. Exp Dermatol 2014; 23: 159-164.
21. Ribatti D, Crivellato E. Mast cells, angiogenesis, tumour growth. Biochim Biophys Acta 2012; 1822: 2-8.
22. Ribatti D. Mast cells as therapeutic target in cancer. Eur j pharmacol 2016; 778: 152-157.
23. Pavone-Macaluso M. Tissue mast cells in renal diseases. Acta pathol microbiol Scand 1960; 50: 337-346.
24. Eddy AA. Mast cells find their way to the kidney. Kidney int 2001; 60: 375-377.
25. Saruta T, Kondo K, Ohguro T, Ozawa Y, Kato E. Mast cells in human kidney cortex. Keio J Med 1977; 26: 163-169.
26. Guldur ME, Kocarslan S, Ozardali HI, Ciftci H, Dincoglu D, Gumus K. The relationship of mast cells and angiogenesis with prognosis in renal cell carcinoma. J Pak Med Assoc 2014; 64: 300-303.
27. Mohseni MG, Mohammadi A, Heshmat AS, Kosari F, Meysamie AP. The lack of correlation between mast cells and microvessel density with pathologic feature of renal cell carcinoma. Int Urol Nephrol 2010; 42: 109-112.
28. Kitamura Y, Oboki K, Ito A. Development of mast cells. Proc Jpn Acad Ser B Phys Biol Sci 2007; 83: 164-174.
29. Kinoshita T, Sawai N, Hidaka E, Yamashita T, Koike K. Interleukin-6 directly modulates stem cell factor-dependent development of human mast cells derived from CD34(+) cord blood cells. Blood 1999; 94: 496-508.
30. Samayawardhena LA, Pallen CJ. Protein-tyrosine phosphatase alpha regulates stem cell factor-dependent c-Kit activation and migration of mast cells. J Biol Chem 2008; 283: 29175-29185.
31. Hollins F, Kaur D, Yang W, Cruse G, Saunders R, Sutcliffe A, et al. Human airway smooth muscle promotes human lung mast cell survival, proliferation, constitutive activation: Cooperative roles for CADM1, stem cell factor, IL-6. J Immunol 2008; 181: 2772-2780.
32. Forster A, Grotha SP, Seeger JM, Rabenhorst A, Gehring M, Raap U, et al. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells. Allergy 2015; 70: 764-774.
33. Zhang W, Stoica G, Tasca SI, Kelly KA, Meininger CJ. Modulation of tumor angiogenesis by stem cell factor. Cancer Res 2000; 60: 6757-6762.
34. Watanabe S, Miyata Y, Matsuo T, Mochizuki Y, Nishikido M, Hayashi T, et al. High density of tryptase-positive mast cells in patients with renal cell carcinoma on hemodialysis: Correlation with expression of stem cell factor and protease activated receptor-2. Hum Pathol 2012; 43: 888-897.
35. Horstmann M, Hennenlotter J, Geiger LM, Vogel U, Schmid H, Kuehs U, et al. Evaluation of the KIT/stem cell factor axis in renal tumours. Anticancer Res 2012; 32: 4339-4345.
36. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553-560.
37. Deville JL, Salas S, Figarella-Branger D, Ouafik L, Daniel L. Adrenomedullin as a therapeutic target in angiogenesis. Expert Opin Ther Targets 2010; 14: 1059-1072.
38. Nikitenko LL, Fox SB, Kehoe S, Rees MC, Bicknell R. Adrenomedullin and tumour angiogenesis. Br J Cancer 2006; 94: 1-7.
39. Deville JL, Bartoli C, Berenguer C, Fernandez-Sauze S, Kaafarani I, Delfino C, et al. Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma. Int J Cancer 2009; 125: 2307-2315.
40. Fujita Y, Mimata H, Nasu N, Nomura T, Nomura Y, Nakagawa M. Involvement of adrenomedullin induced by hypoxia in angiogenesis in human renal cell carcinoma. Int J Urol 2002; 9: 285-295.
41. Park JY, Lin PY, Weiss RH. Targeting the PI3K-Akt pathway in kidney cancer. Expert Rev Anticancer Ther 2007; 7: 863-870.
42. Juengel E, Kim D, Makarevic J, Reiter M, Tsaur I, Bartsch G, et al. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib. J Cell Mol Med 2015; 19: 430-441.
43. Trojan L, Thomas D, Friedrich D, Grobholz R, Knoll T, Alken P, et al. Expression of different vascular endothelial markers in prostate cancer and BPH tissue: An immunohistochemical and clinical evaluation. Anticancer Res 2004; 24: 1651-1656.